Vaxon Biotech

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Kriptic Pharmaceuticals Limited

Jeanne Menez-Jamet

Kostantinos (Kostas) Kosmatopoulos

Stéphanie Graff-Dubois

Pierre Langlade-Demoyen

Sylvain Cardinaud

Kostas Kosmatopoulos

Fransisco Garcia Pons

Christine Neuveut

Olivier Adotevi

Kostantinos Kosmatopoulos

Aude Rougeot

Catherine Gallou

Kostantinos (kostas) Kosmatopoulos

The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.

Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing tert

The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.

Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy

The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).

Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy

The invention provides methods for identifying a HLA-B*-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*-restricted cryptic epitopes. The HLA-B*-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*phenotype.

Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.

Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Growing community of inventors

Montrouge, France

Jeanne Menez-Jamet